Lunit Presents Groundbreaking Examine on Predicting Remedy Response by HER2 Evaluation in Colorectal Most cancers


SEOUL, South Korea, Aug. 1, 2023. Lunit , a number one supplier of AI-powered options for most cancers diagnostics and therapeutics, right this moment introduced the presentation of a groundbreaking research on the ASCO (American Society of Scientific Oncology) Breakthrough convention, to be held from August 3 to August 5 in Yokohama, Japan.

Co-led by Lunit and Dr. Takayuki Yoshino from the Nationwide Most cancers Middle Hospital East (NCCHE), the research reveals a major breakthrough in understanding the connection between the HER2 (Human Epidermal progress issue Receptor 2) detailed expression profile analyzed by AI, and remedy response to Pertuzumab plus Trastuzumab in metastatic colorectal most cancers (mCRC) sufferers. This research showcases the potential of Lunit SCOPE HER2, an AI-powered resolution designed to detect HER2 expression profile intimately, to supply priceless insights that may predict remedy response, thereby advancing personalised medication in mCRC sufferers.

The research utilized HER2 immunohistochemistry (IHC) and H&E-stained whole-slide pictures (WSI) from 30 mCRC sufferers confirmed HER2-positive by means of tumor tissue or circulating tumor DNA (ctDNA) evaluation. Lunit SCOPE HER2 was employed to evaluate HER2 ranges. HER2 depth was categorized into unfavourable, 1+, 2+, or 3+. The research employed a better HER2 cutoff (HER2 3+ greater than 50%) than the requirements utilized in breast and gastric cancers (HER2 3+ greater than 10%).

The findings demonstrated a large variation within the proportion of HER2 3+ tumor cells among the many samples assessed by pathologists. Goal response charges (ORR) for Pertuzumab plus Trastuzumab remedy in the complete affected person group and the HER2 IHC 3+ affected person subgroup assessed by pathologists had been 26.7% and 34.8%, respectively. Importantly, Lunit SCOPE HER2 recognized that the >50% HER2 3+ affected person subgroup had an ORR of 42.1%, which contained all 8 responding sufferers. Per the above, there have been no responders within the subgroup of HER2 3+ 10%-49% or <10%. Furthermore, sufferers with HER2 3+ ≥ 50% demonstrated clinically important enchancment in progression-free survival (PFS) and general survival (OS) in comparison with these with HER2 3+ < 50%.

“This outstanding analysis would be the starting of a revolution that AI expertise will convey to most cancers medication,” stated Dr. Takayuki Yoshino of the Nationwide Most cancers Middle Hospital East (Kashiwa, Chiba), principal investigator of the SCRUM-Japan MONSTAR-SCREEN venture. “This discovering has the potential to convey extra applicable remedy to sufferers, resulting in additional personalised medication. We’re happy that Lunit’s cutting-edge AI-based diagnostic expertise and our venture main the event of therapies will work collectively to convey a brand new method to most cancers remedy.”

“This groundbreaking research marks a major milestone for Lunit and reinforces our dedication to advancing personalised medication in most cancers remedy,” stated Brandon Suh, CEO of Lunit. “The findings from this research reveal the potential of Lunit SCOPE HER2 to supply priceless insights in predicting remedy response for HER2-positive metastatic colorectal most cancers sufferers. We’re excited in regards to the prospects of utilizing AI-powered options to enhance remedy choices and affected person outcomes throughout a broad vary of most cancers varieties.”

This research demonstrates for the primary time that the additional stratification of HER2 3+ CRC sufferers by HER2 expression by way of Lunit SCOPE HER2 has predictive implications for the efficacy of a HER2-targeted therapeutic. Lunit’s ongoing analysis in collaboration with NCCHE and different companions goals to develop this paradigm of HER2 steady expression as a predictor for HER2-targeted therapeutics comparable to monoclonal antibodies and antibody-drug conjugates (ADC).

About Lunit

Lunit is a deep learning-based medical AI firm on a mission to beat most cancers. Our focus is on creating AI options for precision diagnostics and therapeutics, making certain the correct prognosis, and remedy, on the proper price for every affected person. Lunit is dedicated to creating superior medical picture analytics and AI-based biomarkers by way of cutting-edge expertise.

Based in 2013, Lunit has been acknowledged around the globe for its superior, state-of-the-art expertise and its utility in medical pictures. Its expertise has been acknowledged at worldwide AI competitions surpassing giants like Google, IBM, and Microsoft. As a medical AI firm grounded on scientific proof, the corporate’s findings are introduced in main peer-reviewed journals such because the Journal of Scientific Oncology and JAMA Community Open, and international conferences together with ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically utilized in roughly 2,000 hospitals and medical establishments throughout 40+ international locations. Lunit is headquartered in Seoul, South Korea with places of work and representatives worldwide. For extra info, please go to

About Lunit SCOPE

Lunit SCOPE is a collection of AI-powered software program that analyzes tissue slide pictures for digital pathology and AI biomarker improvement, aiming to optimize workflow and facilitate extra correct and predictive scientific information for clinicians and researchers.

Lunit SCOPE platform affords a number of tissue evaluation AI software program merchandise and assays that may streamline digital pathology workflow and diagnostics and improve the drug improvement course of.

Lunit SCOPE IO analyzes the tumor microenvironment (TME) based mostly on H&E evaluation and supplies AI-based predictive scientific final result info. As well as, AI-driven Immunohistochemistry (IHC) slide evaluation companies are provided, by means of merchandise comparable to Lunit SCOPE PD-L1, Lunit SCOPE HER2, Lunit SCOPE ER/PR, and others.


Associated articles

Perjeta (pertuzumab) FDA Approval Historical past


Please enter your comment!
Please enter your name here